



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/12, 9/72	A1	(11) International Publication Number: WO 92/00061 (43) International Publication Date: 9 January 1992 (09.01.92)
(21) International Application Number: PCT/GB91/01023 (22) International Filing Date: 25 June 1991 (25.06.91) (30) Priority data: 9014526.9 29 June 1990 (29.06.90) GB 9014527.7 29 June 1990 (29.06.90) GB 9023953.4 3 November 1990 (03.11.90) GB (71) Applicant (for all designated States except US): FISONS PLC [GB/GB]; Fison House, Princes Street, Ipswich, Suffolk IP1 1QH (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : SOMANI, Asit [GB/GB]; 29 Glebe Street, Loughborough, Leicestershire LE11 1JR (GB). BOOLES, Clive [GB/GB]; 11 Linley Avenue, Shepshed, Leicestershire LE12 9HJ (GB).		(74) Agent: WRIGHT, Robert, Gordon, McRae; Fisons plc, 12 Derby Road, Loughborough, Leicestershire LE11 0BB (GB). (81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report.</i>
(54) Title: PRESSURISED AEROSOL COMPOSITIONS (57) Abstract <p>There are disclosed pressurised aerosol compositions comprising a medicament, a hydrofluorocarbon propellant and a polyethoxylated surfactant, the compositions containing substantially no solvent, other than the propellant, capable of increasing the solubility of the surfactant in the propellant. The compositions according to the invention are advantageous in that the solubility of the surfactant is such as to ensure good dispersion of the medicament and smooth operation of the aerosol valve.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

Pressurised Aerosol Compositions

This invention relates to pressurised aerosol compositions, in particular compositions of powdered inhalation medicaments.

5 Pressurised aerosols for the administration of medicaments, and indeed for other applications, conventionally contain one or more liquified chlorofluorocarbons (CFC's) as propellant. Such materials are suitable for use in such applications since they have
10 the right vapour pressures (or can be mixed in the right proportions to achieve a vapour pressure in the right range) and are essentially taste- and odour-free.

In recent years there has been increasing concern about the depletion of the ozone layer in the upper
15 atmosphere. This is believed to be due to the release into the atmosphere of CFC's and has led to a search for alternative agents for use in all applications of CFC's. To this end, aerosols for many applications are now pressurised using pressurised gases such as nitrogen or
20 hydrocarbons. However, such propellants are generally not suitable for use in the administration of inhalation medicaments since they are toxic and/or the pressure within the canister falls each time the device is used which leads to unreproducible dosing.

25 The use of hydrofluorocarbons as aerosol propellants has also been suggested but this has the disadvantage that other excipients, in particular the surfactants generally used in aerosol formulations, such as sorbitan trioleate and oleic acid, are insufficiently soluble in these
30 materials. Surfactants are required inter alia to ensure good dispersion of the powdered medicament and smooth operation of the valve through which the composition is dispensed.

European Patent Application 0 372 777 offers a
35 solution to the problem of poor solvating properties of the

hydrofluorocarbons by adding to the formulation a solvent, eg ethanol, capable of increasing the solubility of the surfactant in the propellant. This apparent solution suffers from the disadvantage that many of the solvents
5 ("adjuvants") suggested are flammable, toxic and/or affect the stability and dispersion characteristics of the formulation.

Surprisingly, we have found a group of surfactants having a particular structural feature which are
10 sufficiently soluble in hydrofluorocarbon propellants to permit the formulation of satisfactory pressurised aerosol formulations without the need for additional solvents.

Thus, according to the invention there is provided a pressurised aerosol composition comprising a medicament, a
15 hydrofluorocarbon propellant and a polyethoxylated surfactant, the composition containing substantially no solvent, other than the propellant, capable of increasing the solubility of the surfactant in the propellant.

The compositions according to the invention are
20 advantageous in that the solubility of the surfactant is such as to ensure good dispersion of the medicament and smooth operation of the aerosol valve. In addition, certain of the formulations disclosed herein are advantageous over prior art formulations in that they are
25 more stable, are less toxic, have more suitable vapour pressures for the administration of medicaments by inhalation, more readily produced, perform better, eg in dispersion tests carried out using an impinger, or have other advantageous pharmaceutical properties.

The propellant mixtures of the present invention may
30 also be advantageous in that they are substantially taste- and odour-free and have suitable vapour pressures for the administration of medicaments by inhalation, yet are environmentally safe and acceptable, especially when
35 compared with compositions including chlorofluorocarbons.


In addition, they may be less irritant than corresponding compositions including conventional surfactants such as oleic acid and sorbitan trioleate.

We prefer surfactants which have an average number, n, of from 2 - 50, more preferably 2 - 40, particularly 2 - 30, and especially 4 - 20, polyethoxylate units per molecule of surfactant.

Although the surfactant may consist completely of polyethoxylate units, ie is polyethylene glycol, eg having an average molecular weight of from 200 to 4000, we prefer surfactants in which the polyethoxylated portion is from 10 - 90%, more preferably 10 - 70%, particularly 10 - 50% by weight of the surfactant.

We prefer surfactants having an average molecular weight of less than 20,000, more preferably less than 10,000 and particularly less than 5000. We prefer surfactants having an average molecular weight greater than 200, more preferably 400 and especially 1000.

We prefer surfactants which are block copolymers of ethylene oxide and propylene oxide, particularly those polymers known as poloxamers. These surfactants have the general formula



in which a and c are generally in the range 2 to 130 and b is in the range 15 to 67; these compounds are block copolymers with the polyethoxylate portions accounting for between 20 and 90% by weight. These surfactants are available under the registered trademark Synperonic PE (ICI) and the registered trademark Pluronic (BASF). Particularly suitable poloxamers include the following Synperonic PE surfactants:

L35, L42, L44, L61, L62, L62F, L64, L75, L81, P85, L92 P94, L101 and L121;

in which L indicates that the surfactants are liquids, P that they are pastes, the first digit is a measure of the


molecular weight of the polypropylene portion of the surfactant and the last digit of the number, multiplied by 10, gives the per cent ethylene oxide content of the surfactant. Further characterising details of these surfactants, and the majority of surfactants described herein, are given in Surfactants Europa, 2nd Edition, 1989, compiled and edited by Gordon L Hollis and published by Tergo-Data, the entire contents of which are hereby incorporated by reference.

Other suitable poloxamers include the following Pluronic PE surfactants:

3100, 4300, 6100, 6200, 6400, 8100 and 9200.

We prefer poloxamers which contain less than 60% by weight of ethylene oxide.

We also prefer block copolymers of ethylene oxide in which a polyethylene glycol moiety has been used as the initiator molecule for the polymerisation, giving compounds of the general formula:




which typically have a molecular weight of the order of 3000 with the ethylene oxide portions accounting for typically 10-20% by weight; these compounds are available under the tradename Synperonic RPE (ICI) and Pluronic RPE (BASF). Especially preferred surfactants include Pluronic RPE2510, RPE2520 and RPE3110.

We prefer surfactants having a hydrophobic portion derived from an alkylphenol, an alcohol or ethylenediamine.

Particular surfactants derived from an alkylphenol that may be mentioned include

a) compounds of the general formula




in which n represents the average number of ethoxylate groups per molecule; these compounds are available under

- 5 -

the registered trademark Synperonic OP (ICI), and

b) compounds of the general formula




in which n represents the mean number of ethoxylate groups per molecule; these compounds are available under the tradename Synperonic NP (ICI). Suitable examples of these surfactants include the following Synperonic surfactants:

NP4, NP5, NP6, NP7, NP8, NP9, NP10, NP12, NP15, OP10 and OP11.

Alcohol derived surfactants may be derived from a mono-hydric or polyhydric alcohol. Particular mono-hydric alcohols that may be mentioned include straight or branched chain C_8 to C_{20} alcohols. Suitable surfactants that may be mentioned include the alcohol ethoxylates available under the tradename Synperonic LF (ICI).

Polyhydric alcohols from which the surfactant may be derived include glycerol and sorbitan. The polyhydric alcohol may be partially esterified, eg, with a fatty carboxylic acid, such as lauric, palmitic and especially oleic acid. We particularly prefer surfactants which are polyethoxylated derivatives of sorbitan mono-oleate, for example, polysorbate 20, 40, 60 and 80.

Surfactants having a portion derived from ethylenediamine that may be particularly mentioned include the Synperonic T series of compounds (ICI) of general formula



in which x and y are in the ranges 4-25 and 1-120 respectively. Particular examples of these surfactants

that may be specifically mentioned include Synperonic T701,

T304 and T702.

In the present context, the term 'hydrofluorocarbon' is to be taken to mean a compound of general formula



5 in which x is an integer from 1 to 3, $y+z=2x+2$ and y and z are both at least 1.

Particular hydrofluorocarbons of interest are CF_3CFH_2 (Propellant 134a), CH_3CHF_2 (Propellant 152a) and CF_3CHFCF_3 (Propellant 227). We particularly
10 prefer formulations containing Propellant 227.

In general the vapour pressure of the mixture should be in the range suitable and permitted for aerosol propellants. The vapour pressure may be varied by mixing one or more hydrofluorocarbons and/or some other suitable
15 vapour pressure modifying agent in appropriate proportions.

We prefer the vapour pressure of the mixture to be in the range 20 to 100 psi, more preferably 40 to 80 psi, eg about 60 psi.

The amount of surfactant in the composition will
20 generally be from about 0.01 to 10% by weight, more preferably from about 0.1 to 5%, eg about 1%.

The compositions according to the invention may be used in a wide variety of fields, with the active ingredient being chosen appropriately, but the properties
25 of the invention, notably the absence of any co-solvent for the surfactant, render it particularly useful in the pharmaceutical field.

The medicament may be in solid, particulate form (ie the composition may be a suspension), or the active
30 ingredient may be dissolved in the propellant.

Medicaments which may be dispersed in the composition according to the invention include any medicaments which are conventionally administered by inhalation of a pressurised aerosol formulation. Such medicaments include
35 drugs for use in the prophylactic or remedial treatment of

reversible obstructive airways disease, eg drugs such as sodium cromoglycate, nedocromil sodium, inhaled steroids such as beclomethasone dipropionate, tipredane, fluticasone, anticholinergic agents such as ipratropium bromide, and bronchodilators, eg salmeterol, salbutamol, reproterol, terbutaline, fenoterol and salts thereof. We find that the formulations are particularly advantageous for formulating salts of carboxylic acids, particularly dicarboxylic acids such as nedocromil and cromoglycic acid.

Where the medicament is solid, it preferably has a particle size distribution such that a high proportion of the particles are of a size capable of penetrating deep into the lung. In particular, the active ingredient is preferably in a form having a mass median diameter of from 0.1 to 10 μm , more preferably from 0.1 to 4 μm , eg about 2 or 3 μm .

We prefer the active ingredient to have a mass median diameter in the range 0.01 to 10 microns, more preferably from 1 to 5 microns. The composition preferably comprises from 0.05 to 15, preferably from 0.1 to 10, and most preferably from 0.5 to 5% w/w of the active ingredient.

In producing the compositions according to the invention, a container equipped with a valve is filled with a propellant containing the finely-divided medicament. The container may first be charged with a weighed amount of medicament which has been ground to a predetermined particle size, or with a slurry of powder in the cooled liquid propellant. The container may alternatively be filled by introducing powder and propellant by the normal cold filling method, or a slurry of the powder in one component of the propellant may be placed in the container, the valve sealed in place, and the balance of the propellant then introduced by pressure filling through the valve nozzle. As a further alternative a bulk quantity of the total composition may be filled into the container

through the valve.

The invention is illustrated by the following example:

Example

5 Compositions were prepared by cold filling of the ingredients into aluminium aerosol cannisters which were then sealed by crimping a 50 μ l or 100 μ l aerosol valve in place.

The following combinations of micronised active ingredient, surfactant and propellant were used:

10

1.	Nedocromil sodium	0.2000 g
	Synperonic PEL 62	0.0612 g
	HFC 134a	11.9788 g

15

2.	Nedocromil sodium	0.2000 g
	Pluronic PE 6200	0.0612 g
	HFC 134a	11.9788 g

20

3.	Nedocromil sodium	0.2000 g
	Synperonic NP 15	0.0612 g
	HFC 134a	11.9788 g

25

4.	Nedocromil sodium	0.2000 g
	Synperonic PEL 62	0.0706 g
	HFC 227	13.8494 g

30

5.	Nedocromil sodium	0.2000 g
	Pluronic PE 6200	0.0706 g
	HFC 227	13.8494 g

6.	Nedocromil sodium	0.2000 g
	Synperonic NP15	0.0706 g
	HFC 227	13.8494 g

35

7.	Sodium cromoglycate	0.5000 g
----	---------------------	----------

		Synperonic PEL 62	0.0612 g
		HFC 134a	11.6788 g
5	8.	Sodium cromoglycate	0.5000 g
		Pluronic PE 6200	0.0612 g
		HFC 134a	11.6788 g
	9.	Sodium cromoglycate	0.5000 g
		Synperonic NP 15	0.0612 g
10		HFC 134a	11.6788 g
	10.	Sodium cromoglycate	0.5000 g
		Synperonic PEL 62	0.0706 g
		HFC 227	13.5494 g
15			
	11.	Sodium cromoglycate	0.5000 g
		Pluronic PE 6200	0.0706 g
		HFC 227	13.5494 g
20	12.	Sodium cromoglycate	0.5000 g
		Synperonic NP 15	0.0706 g
		HFC 227	13.5494 g
	13.	Nedocromil sodium	0.2000 g
25		Polyethylene glycol PEG 200	0.0706 g
		HFC 227	13.8494 g
	14.	Nedocromil sodium	0.2000 g
		Polyethylene glycol PEG 600	0.0706 g
30		HFC 227	13.8494 g
	15.	Nedocromil sodium	0.2000 g
		Polysorbate 80	0.0706 g
		HFC 227	13.8494 g
35			

- 10 -

	16.	Nedocromil sodium	0.2000 g
		Polysorbate 20	0.0706 g
		HFC 227	13.8494 g
5	17.	Nedocromil sodium	0.2000 g
		Polysorbate 80	0.0122 g
		HFC 134a	12.0278 g
	18.	Nedocromil sodium	0.2000 g
10		Synperonic PEP 85	0.0122 g
		HFC 134a	12.0278 g

In all cases stable suspensions of the active ingredient in the propellant were obtained.

15

20

25

30

35

Claims

1. A pressurised aerosol composition comprising a medicament, a hydrofluorocarbon propellant and a polyethoxylated surfactant, the composition containing
5 substantially no solvent, other than the propellant, capable of increasing the solubility of the surfactant in the propellant.
2. A composition according to Claim 1, wherein the surfactant has an average number of from 2 - 50
10 polyethoxylate units per molecule of surfactant.
3. A composition according to Claim 1 or 2, wherein the surfactant is a block copolymer of ethylene oxide and propylene oxide.
4. A composition according to Claim 1 or 2, wherein the
15 surfactant has a hydrophobic portion derived from an alkylphenol, an alcohol or ethylenediamine.
5. A composition according to Claim 4, wherein the alcohol is a monohydric alcohol.
6. A composition according to Claim 4, wherein the
20 alcohol is polyhydric.
7. A composition according to Claim 6, wherein the polyhydric alcohol is partially esterified.
8. A composition according to any one of Claims 1, 2, 4, 5, 6 or 7, wherein the surfactant is polysorbate 20,
25 polysorbate 40, polysorbate 60 or polysorbate 80.
9. A composition according to any one of the preceding Claims, wherein the propellant is selected from propellant 134a, propellant 152a and propellant 227.
10. A composition according to any one of the preceding
30 Claims, wherein the propellant is propellant 227.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 91/01023

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.C1.5 A 61 K 9/12 A 61 K 9/72		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.C1.5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ^o	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0372777 (RIKER) 13 June 1990, see the claims (cited in the application) ---	1-10
A	WO,A,8807855 (FISONS) 20 October 1988, see claims 1-9; page 5, lines 14-15; page 8, lines 20-22; page 9, lines 5-7 ---	1-10
A	GB,A,2046093 (AMERICAN HOME PRODUCTS) 12 November 1980, see claims 1-10 ---	1-10
P,X	WO,A,9011754 (FISONS) 18 October 1990, see claims 1-5,8,10; page 7, lines 2-3; page 9, lines 3-4,15-16; page 12, lines 3-6,14-16 -----	1-2,6-9
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>^o Special categories of cited documents : ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
09-09-1991	22. 10. 91	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	Falk Heck	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9101023
SA 48823

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 26/09/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0372777	13-06-90	AU-A- 4595689 CA-A- 2004598 JP-A- 2200627	14-06-90 06-06-90 08-08-90
WO-A- 8807855	20-10-88	EP-A- 0309519 JP-T- 1502828	05-04-89 28-09-89
GB-A- 2046093	12-11-80	CA-A- 1136547 US-A- 4600575	30-11-82 15-07-86
WO-A- 9011754	18-10-90	None	